Anti-tumor response; Metabolic reprogramming; Metabolism; T cell; Tumor microenvironment; B7-H1 Antigen; PDCD1 protein, human; Programmed Cell Death 1 Receptor; Reactive Oxygen Species; B7-H1 Antigen/antagonists & inhibitors; Energy Metabolism; Glycolysis; Humans; Immunotherapy; Neoplasms/immunology; Programmed Cell Death 1 Receptor/physiology; Reactive Oxygen Species/metabolism; T-Lymphocytes/metabolism; Tumor Escape; Tumor Microenvironment; Neoplasms; T-Lymphocytes; Oncology; Cancer Research
Abstract :
[en] T cells represent the major contributors to antitumor-specific immunity among the tumor-infiltrating lymphocytes. However, tumors acquire ways to evade immunosurveillance and anti-tumor responses are too weak to eradicate the disease. T cells are often functionally impaired as a result of interaction with, or signals from, transformed cells and the tumor microenvironment, including stromal cells. Among these, nutrients use and consumption is critically important for the control of differentiation and effector mechanisms of T cells. Moreover, Treg cells-skewing conditions often coexist within the cancer milieu, which sustains the notion of immune privileged tumors. Additionally, cancer cells contend with tumor infiltrating lymphocytes for nutrients and can outcompete the immune response. PD1- and CTLA-based immunotherapies partially remodel cell metabolism leading the way to clinical approaches of metabolic reprogramming for therapeutic purposes. Here we shortly discuss T cell fates during anti-tumor immune responses and how signals within tumor microenvironment influence T cell metabolism, altering functions and longevity of the cell.
Disciplines :
Oncology
Author, co-author :
Franchina, Davide G; Department of Infection and Immunity, Experimental and Molecular Immunology, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg
He, Feng; Department of Infection and Immunity, Immune Systems Biology, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg
BRENNER, Dirk ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Immunology and Genetics ; Department of Infection and Immunity, Experimental and Molecular Immunology, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg, Odense Research Center for Anaphylaxis (ORCA), Department of Dermatology and Allergy Center, Odense University Hospital, University of Southern Denmark, Odense, Denmark. Electronic address: dirk.brenner@lih.lu
External co-authors :
no
Language :
English
Title :
Survival of the fittest: Cancer challenges T cell metabolism.
We thank the Luxembourg National Research Fund (FNR) for support: D.B. is funded through the FNR -ATTRACT program ( A14/7632103 ) and a FNR -CORE grant ( C15/BM/10355103 ). D.B., F.H. and D.G.F. are supported through the FNR -RIKEN and FNR -PRIDE funding schemes.
Pollizzi, K.N., Powell, J.D., Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat. Rev. Immunol. 14 (2014), 435–446.
Kouidhi, S., Noman, M.Z., Kieda, C., Elgaaied, A.B., Chouaib, S., Intrinsic and tumor microenvironment-induced metabolism adaptations of T cells and impact on their differentiation and function. Front. Immunol., 7, 2016, 114.
Molon, B., Cali, B., Viola, A., T Cells and cancer: how metabolism shapes immunity. Front. Immunol., 7, 2016, 20.
Brand, K.A., Hermfisse, U., Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J. 11 (1997), 388–395.
van der Windt, G.J., Everts, B., Chang, C.H., Curtis, J.D., Freitas, T.C., Amiel, E., et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36 (2012), 68–78.
Pfeiffer, T., Schuster, S., Bonhoeffer, S., Cooperation and competition in the evolution of ATP-producing pathways. Science 292 (2001), 504–507.
Sukumar, M., Liu, J., Ji, Y., Subramanian, M., Crompton, J.G., Yu, Z., et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J. Clin. Invest. 123 (2013), 4479–4488.
Wang, R., Dillon, C.P., Shi, L.Z., Milasta, S., Carter, R., Finkelstein, D., et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35 (2011), 871–882.
Buck, M.D., O'Sullivan, D., Klein Geltink, R.I., Curtis, J.D., Chang, C.H., Sanin, D.E., et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell 166 (2016), 63–76.
Owen, O.E., Kalhan, S.C., Hanson, R.W., The key role of anaplerosis and cataplerosis for citric acid cycle function. J. Biol. Chem. 277 (2002), 30409–30412.
Gomes, A.P., Blenis, J., A nexus for cellular homeostasis: the interplay between metabolic and signal transduction pathways. Curr. Opin. Biotechnol. 34 (2015), 110–117.
Vinay, D.S., Ryan, E.P., Pawelec, G., Talib, W.H., Stagg, J., Elkord, E., et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin. Cancer Biol.(Suppl. 35), 2015, S185–S198.
Dang, C.V., Links between metabolism and cancer. Genes Dev. 26 (2012), 877–890.
Prasetyanti, P.R., Medema, J.P., Intra-tumor heterogeneity from a cancer stem cell perspective. Mol. Cancer, 16, 2017, 41.
Gupta, S., Roy, A., Dwarakanath, B.S., Metabolic cooperation and competition in the tumor microenvironment: implications for therapy. Front. Oncol., 7, 2017, 68.
Kalluri, R., The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16 (2016), 582–598.
Wang, Y., Chu, Y., Yue, B., Ma, X., Zhang, G., Xiang, H., et al. Adipose-derived mesenchymal stem cells promote osteosarcoma proliferation and metastasis by activating the STAT3 pathway. Oncotarget 8 (2017), 23803–23816.
Whitaker-Menezes, D., Martinez-Outschoorn, U.E., Lin, Z., Ertel, A., Flomenberg, N., Witkiewicz, A.K., et al. Evidence for a stromal-epithelial “lactate shuttle” in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 10 (2011), 1772–1783.
Fiaschi, T., Marini, A., Giannoni, E., Taddei, M.L., Gandellini, P., De Donatis, A., et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res. 72 (2012), 5130–5140.
Martinez-Outschoorn, U.E., Lisanti, M.P., Sotgia, F., Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin. Cancer Biol. 25 (2014), 47–60.
Shi, H., Jiang, H., Wang, L., Cao, Y., Liu, P., Xu, X., et al. Overexpression of monocarboxylate anion transporter 1 and 4 in T24-induced cancer-associated fibroblasts regulates the progression of bladder cancer cells in a 3D microfluidic device. Cell Cycle 14 (2015), 3058–3065.
Colegio, O.R., Chu, N.Q., Szabo, A.L., Chu, T., Rhebergen, A.M., Jairam, V., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513 (2014), 559–563.
Webb, B.A., Chimenti, M., Jacobson, M.P., Barber, D.L., Dysregulated pH: a perfect storm for cancer progression. Nat. Rev. Cancer 11 (2011), 671–677.
Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
Warburg, O., On the origin of cancer cells. Science 123 (1956), 309–314.
Jones, R.G., Thompson, C.B., Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 23 (2009), 537–548.
Haider, S., McIntyre, A., van Stiphout, R.G., Winchester, L.M., Wigfield, S., Harris, A.L., et al. Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. Genome Biol., 17, 2016, 140.
Frezza, C., Gottlieb, E., Mitochondria in cancer: not just innocent bystanders. Semin. Cancer Biol. 19 (2009), 4–11.
Pasteur, L., Experiences et vues nouvelles sur la nature des fermentations. C R. Acad. Sci. 52 (1861), 1260–1264.
Krebs, H.A., The Pasteur effect and the relations between respiration and fermentation. Essays Biochem., 1972, 1–34.
Groussard, C., Morel, I., Chevanne, M., Monnier, M., Cillard, J., Delamarche, A., Free radical scavenging and antioxidant effects of lactate ion: an in vitro study. J. Appl. Physiol. 89:2000 (1985), 169–175.
Le, A., Cooper, C.R., Gouw, A.M., Dinavahi, R., Maitra, A., Deck, L.M., et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 2037–2042.
Harris, I.S., Treloar, A.E., Inoue, S., Sasaki, M., Gorrini, C., Lee, K.C., et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27 (2015), 211–222.
Gorrini, C., Harris, I.S., Mak, T.W., Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12 (2013), 931–947.
Chang, C.H., Qiu, J., O'Sullivan, D., Buck, M.D., Noguchi, T., Curtis, J.D., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162 (2015), 1229–1241.
Ho, P.C., Bihuniak, J.D., Macintyre, A.N., Staron, M., Liu, X., Amezquita, R., et al. Phosphoenolpyruvate Is a metabolic checkpoint of anti-tumor t cell responses. Cell 162 (2015), 1217–1228.
Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
van Stipdonk, M.J., Hardenberg, G., Bijker, M.S., Lemmens, E.E., Droin, N.M., Green, D.R., et al. Dynamic programming of CD8+ T lymphocyte responses. Nat. Immunol. 4 (2003), 361–365.
Buck, M.D., O'Sullivan, D., Pearce, E.L., T cell metabolism drives immunity. J. Exp. Med. 212 (2015), 1345–1360.
O'Neill, L.A., Kishton, R.J., Rathmell, J., A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 16 (2016), 553–565.
Wang, B.T., Ducker, G.S., Barczak, A.J., Barbeau, R., Erle, D.J., Shokat, K.M., The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 15201–15206.
Mak, T.W., Grusdat, M., Duncan, G.S., Dostert, C., Nonnenmacher, Y., Cox, M., et al. Glutathione primes T cell metabolism for inflammation. Immunity 46 (2017), 675–689.
Shimobayashi, M., Hall, M.N., Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat. Rev. Mol. Cell Biol. 15 (2014), 155–162.
Dang, C.V., Le, A., Gao, P., MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 15 (2009), 6479–6483.
Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat. Rev. Cancer 11 (2011), 85–95.
Vafa, O., Wade, M., Beeche, M., Hampton, G.M., Kern, S., Pandita, T.K., et al. c-Myc can induce DNA Damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell 9 (2002), 1031–1044.
Martinez-Reyes, I., Diebold, L.P., Kong, H., Schieber, M., Huang, H., Hensley, C.T., et al. Potential are necessary for diverse biological functions. Mol. Cell 61 (2016), 199–209.
Devadas, S., Zaritskaya, L., Rhee, S.G., Oberley, L., Williams, M.S., Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and fas ligand expression. J. Exp. Med., 2002, 59–70.
Laplante, M., Sabatini, D.M., mTOR signaling in growth control and disease. Cell 149 (2012), 274–293.
Semenza, G.L., Hypoxia-inducible factors in physiology and medicine. Cell 148 (2012), 399–408.
Dang, E.V., Barbi, J., Yang, H.Y., Jinasena, D., Yu, H., Zheng, Y., et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146 (2011), 772–784.
Shi, L.Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D.R., et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208 (2011), 1367–1376.
Clambey, E.T., McNamee, E.N., Westrich, J.A., Glover, L.E., Campbell, E.L., Jedlicka, P., et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E2784–E2793.
Wang, R., Green, D.R., Metabolic checkpoints in activated T cells. Nat. Immunol. 13 (2012), 907–915.
Siska, P.J., Rathmell, J.C., T cell metabolic fitness in antitumor immunity. Trends Immunol. 36 (2015), 257–264.
Klysz, D., Tai, X., Robert, P.A., Craveiro, M., Cretenet, G., Oburoglu, L., et al. Glutamine-dependent alpha-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci. Signal, 8, 2015 ra97.
Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004), 942–949.
Shang, B., Liu, Y., Jiang, S.J., Liu, Y., Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci. Rep., 5, 2015, 15179.
Zeng, H., Chi, H., mTOR signaling and transcriptional regulation in T lymphocytes. Transcription, 5, 2014, e28263.
Man, K., Miasari, M., Shi, W., Xin, A., Henstridge, D.C., Preston, S., et al. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat. Immunol. 14 (2013), 1155–1165.
Yao, S., Buzo, B.F., Pham, D., Jiang, L., Taparowsky, E.J., Kaplan, M.H., et al. Interferon regulatory factor 4 sustains CD8 (+) T cell expansion and effector differentiation. Immunity 39 (2013), 833–845.
Shackelford, D.B., Shaw, R.J., The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9 (2009), 563–575.
Kuhajda, F.P., AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int. J. Obes. (Lond) 4:Suppl. 32 (2008), S36–S41.
Jones, R.G., Plas, D.R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18 (2005), 283–293.
Inoki, K., Zhu, T., Guan, K.L., TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003), 577–590.
Delgoffe, G.M., Kole, T.P., Zheng, Y., Zarek, P.E., Matthews, K.L., Xiao, B., et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30 (2009), 832–844.
Michalek, R.D., Gerriets, V.A., Jacobs, S.R., Macintyre, A.N., MacIver, N.J., Mason, E.F., et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186 (2011), 3299–3303.
Ho, P.C., Liu, P.S., Metabolic communication in tumors: a new layer of immunoregulation for immune evasion. J. Immunother. Cancer, 4, 2016, 4.
Nosho, K., Baba, Y., Tanaka, N., Shima, K., Hayashi, M., Meyerhardt, J.A., et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J. Pathol. 222 (2010), 350–366.
Greenwald, R.J., Freeman, G.J., Sharpe, A.H., The B7 family revisited. Annu. Rev. Immunol. 23 (2005), 515–548.
Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33 (2015), 1974–1982.
Waterhouse, P., Penninger, J.M., Timms, E., Wakeham, A., Shahinian, A., Lee, K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270 (1995), 985–988.
Leach, D.R., Krummel, M.F., Allison, J.P., Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996), 1734–1736.
Wolchok, J.D., Hodi, F.S., Weber, J.S., Allison, J.P., Urba, W.J., Robert, C., et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann. N. Y. Acad. Sci. 1291 (2013), 1–13.
Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
Jin, H.T., Ahmed, R., Okazaki, T., Role of PD-1 in regulating T-cell immunity. Curr. Top. Microbiol. Immunol. 350 (2011), 17–37.
Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006), 682–687.
Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., Wunderlich, J.R., Dudley, M.E., White, D.E., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114 (2009), 1537–1544.
Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002), 793–800.
Sheppard, K.A., Fitz, L.J., Lee, J.M., Benander, C., George, J.A., Wooters, J., et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 574 (2004), 37–41.
Parry, R.V., Chemnitz, J.M., Frauwirth, K.A., Lanfranco, A.R., Braunstein, I., Kobayashi, S.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell Biol. 25 (2005), 9543–9553.
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., Saito, T., Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209 (2012), 1201–1217.
Chinai, J.M., Janakiram, M., Chen, F., Chen, W., Kaplan, M., Zang, X., New immunotherapies targeting the PD-1 pathway. Trends Pharmacol. Sci. 36 (2015), 587–595.
Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L.N., et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun., 6, 2015, 6692.
Chang, C.H., Curtis, J.D., Maggi, L.B. Jr., Faubert, B., Villarino, A.V., O'Sullivan, D., et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153 (2013), 1239–1251.
Pedicord, V.A., Cross, J.R., Montalvo-Ortiz, W., Miller, M.L., Allison, J.P., Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. J. Immunol. 194 (2015), 2089–2098.
Staron, M.M., Gray, S.M., Marshall, H.D., Parish, I.A., Chen, J.H., Perry, C.J., et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity 41 (2014), 802–814.
Chamoto, K., Chowdhury, P.S., Kumar, A., Sonomura, K., Matsuda, F., Fagarasan, S., et al. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), E761–E770.
Krummel, M.F., Allison, J.P., CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182 (1995), 459–465.
Vanasek, T.L., Khoruts, A., Zell, T., Mueller, D.L., Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J. Immunol. 167 (2001), 5636–5644.
Tanaka, A., Sakaguchi, S., Regulatory T cells in cancer immunotherapy. Cell Res. 27 (2017), 109–118.
Francisco, L.M., Salinas, V.H., Brown, K.E., Vanguri, V.K., Freeman, G.J., Kuchroo, V.K., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206 (2009), 3015–3029.
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192 (2000), 303–310.
Read, S., Malmström, V., Powrie, F., Cytotoxic T Lymphocyte–associated antigen 4 plays an essential role in the function of CD25+ CD4+ regulatory cells that control intestinal inflammation. J. Exp. Med., 2000, 295–302.
Walker, L.S., Treg and CTLA-4: two intertwining pathways to immune tolerance. J. Autoimmun. 45 (2013), 49–57.
Zeng, H., Yang, K., Cloer, C., Neale, G., Vogel, P., Chi, H., mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature 499 (2013), 485–490.
Rahman, M., Hasan, M.R., Cancer Metabolism and drug resistance. Metabolites 5 (2015), 571–600.
Kasznicki, J., Sliwinska, A., Drzewoski, J., Metformin in cancer prevention and therapy. Ann. Transl. Med., 2, 2014, 57.
Chae, Y.K., Arya, A., Malecek, M.K., Shin, D.S., Carneiro, B., Chandra, S., et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget 7 (2016), 40767–40780.
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., Viollet, B., Metformin: from mechanisms of action to therapies. Cell Metab. 20 (2014), 953–966.
Vazquez-Martin, A., Oliveras-Ferraros, C., Menendez, J.A., The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8 (2009), 88–96.
Zakikhani, M., Blouin, M.J., Piura, E., Pollak, M.N., Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res. Treat. 123 (2010), 271–279.
Zhou, X., Chen, J., Yi, G., Deng, M., Liu, H., Liang, M., et al. Metformin suppresses hypoxia-induced stabilization of HIF-1alpha through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget 7 (2016), 873–884.
